Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $22 to $17.
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $22 to $17.